Search results for "Residual stenosis"

showing 5 items of 5 documents

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Analysis of risk factors for restenosis after PTCA

1990

To identify risk factors for restenosis, we evaluated data in 473 patients with single-vessel percutaneous transluminal coronary angioplasty (PTCA) and control angiography after 6 months. Restenosis, defined as (1) loss greater than 50% of the initial gain, and (2) stenosis greater than 50% was found in 138 patients (29.2%). Univariate analysis revealed eight factors related to restenosis: (1) duration of symptoms less than 1 month (P = 0.005), (2) unstable angina (P = 0.004), (3) high-grade stenosis before PTCA (P = 0.014), (4) large residual stenosis after PTCA (P = 0.001), (5) insufficient improvement of stenosis (P = 0.042), (6) prolonged single inflation time (P = 0.017), (7) prolonged…

Malemedicine.medical_specialtyPercutaneous transluminal coronary angioplastyCoronary DiseaseCoronary AngiographyRestenosisRecurrenceRisk FactorsInternal medicinemedicineHumansAngina Unstablecardiovascular diseasesAngioplasty Balloon CoronaryAgedAnalysis of VarianceUnivariate analysismedicine.diagnostic_testbusiness.industryUnstable anginaResidual stenosisMiddle Agedmedicine.diseaseCoronary VesselsStenosisAngiographyCardiologyEvaluated dataCardiology and Cardiovascular MedicinebusinessCatheterization and Cardiovascular Diagnosis
researchProduct

Coronary stent implantation in acute vessel closure 48 hours after an unsatisfactory coronary angioplasty

1990

We report the implantation of a balloon-expandable stent in a patient with acute vessel closure in the state of evolving myocardial infarction following 48 hr after unsatisfactory coronary angioplasty. The stent was implanted after successful recanalization of an occluded left anterior descending artery, with repeated unsatisfactory results of balloon angioplasty. Adjunct thrombolytic therapy was contraindicated. No residual stenosis was documented in immediate control angiograms, or after 24 hr, 3 weeks, and 4 months.

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentCoronary DiseaseCoronary AngiographyBalloonAngioplastyInternal medicineCoronary stentmedicineHumansAngina Unstablecardiovascular diseasesMyocardial infarctionAngioplasty Balloon Coronarybusiness.industryStentResidual stenosisMiddle Agedmedicine.diseaseCoronary VesselsSurgerymedicine.anatomical_structureCardiologyStentsCardiology and Cardiovascular MedicineComplicationbusinessArteryCatheterization and Cardiovascular Diagnosis
researchProduct

Factors Correlating with Restenosis after PTCA

1991

Since its introduction in 1977 [7, 8], PTCA has been widely used in patients with coronary artery disease. Restenosis with recurrence of angina remains the major problem, limiting the long-term success after PTCA. Reported restenosis rates vary from 17% to 47% [9–19, 22–26]. In larger series [12, 15, 26] a restenosis rate of about 30% was constantly found, irrespective of the definition of restenosis in use.

medicine.medical_specialtyUnstable anginabusiness.industryLimitingResidual stenosismedicine.diseaseAnginaCoronary artery diseaseRestenosisInternal medicinemedicineCardiologyIn patientbusiness
researchProduct

Coronary Angioplasty in Unstable Angina

1990

When Gruntzig introduced the revolutionary method of percutaneous transluminal coronary angioplasty (PTCA) for the treatment of coronary artery stenoses, he initially devoted this technique only to patients with stable angina pectoris [8]. Very soon, however, it was discovered simultaneously by Williams et al. [19] and by our group [12] that this method can also be used in patients with unstable angina pectoris. The earliest experiences with PTCA in 1980 were published by our two groups (Table 1). In these series the average degree of stenosis was somewhat lower than that today, while the residual stenosis after treatment was slightly higher. The very rough balloons and guiding catheters av…

medicine.medical_specialtyUnstable anginabusiness.industrymedicine.medical_treatmentResidual stenosismedicine.diseaseStable anginaStenosisCathetermedicine.anatomical_structureAngioplastyInternal medicinemedicineCardiologyIn patientcardiovascular diseasesbusinessArtery
researchProduct